Fat in the liver is now described as metabolic dysfunction-associated steatotic liver disease, or MASLD, and the older label NAFLD covered much of the same ground before the naming rules changed 1. Research suggests that MASLD is common among adults worldwide 2. This page is about steatosis, the fat itself, rather than the scarring that can follow it.
Studies indicate that many people with MASLD have no symptoms and are identified when bloodwork or imaging is done for another reason 3. That is the single most useful thing to understand about this topic. Waiting for a symptom is a poor detection strategy, because the liver rarely produces one until a lot has already happened.
Most liver fat comes from everyday metabolic load rather than from a single illness, so the usual drivers are food volume, activity, body composition, alcohol, sleep and life stage. None of those are lab findings. They are habits and circumstances, and they tend to stack rather than act alone.
Research suggests that insulin resistance and excess energy intake drive the accumulation of fat inside liver cells 4. In plain terms, when more energy arrives than the body is using, the liver becomes a storage site. Low muscle mass and long sedentary stretches reduce where else that energy can go.
Metabolic conditions travel with this picture. A consensus report from the American Diabetes Association recommends screening for steatotic liver disease in people with type 2 diabetes, which reflects how often the two appear together 5.
Then there are the ordinary things. Short sleep, shift work and long stressful stretches change appetite, food choices and training consistency, which is why a clinician asks about them before reaching for another test. Rapid weight change in either direction matters. Life stage matters too, since body composition and hormonal patterns shift with age. A clinician will also review your medication list, because medicines are one of the things considered whenever liver tests move.
When symptoms do turn up, they are easy to misread. Tiredness, a vague heaviness under the right ribs and mental fog are the usual descriptions. A systematic review and meta-analysis found that MASLD is associated with cognitive impairment, which is one reason brain fog comes up so often in these conversations 7.
No blood test measures liver fat directly, but five markers give a clinician the enzyme and metabolic context that makes fat in the liver more or less likely.
| Marker | Why it is linked to this symptom | What a result can and cannot tell you |
|---|---|---|
| ALT | An enzyme concentrated inside liver cells that appears in blood when those cells are under strain. | A raised value flags liver cell activity worth explaining. It cannot say what is causing it, and a normal value does not rule steatosis out. |
| AST | An enzyme found in liver cells and also in skeletal muscle, heart muscle and red blood cells. | Read next to ALT it helps a clinician judge the pattern. On its own it can reflect muscle rather than liver. |
| GGT | An enzyme on the cells lining the small bile ducts that responds to bile flow and to alcohol intake. | It adds context to an enzyme pattern and prompts questions about drinking. It is not specific to any single cause. |
| Triglycerides | A blood fat the liver packages and exports, which moves with insulin resistance. | A high fasting value is one of the metabolic features a clinician weighs. It says nothing about liver structure. |
| Fasting Insulin | Reflects how hard the pancreas is working to keep glucose in range. | A high value points toward insulin resistance worth discussing. It is not a diagnosis, and it shifts with recent food and sleep. |
Typical lab reference ranges for these markers look roughly like this.
| Marker | Typical reference range | Units |
|---|---|---|
| ALT | 7 to 56 | U/L |
| AST | 10 to 40 | U/L |
| GGT | 9 to 48 | U/L |
| Triglycerides, fasting | under 150 | mg/dL |
| Fasting insulin | 2 to 25 | µIU/mL |
These are typical lab reference ranges, not targets. Ranges vary by lab, age and sex, so the numbers printed beside your own results are the ones that apply to you.
It can be one of the first clues, though a raised ALT only tells you that liver cells are releasing more enzyme than usual, not why. ALT, alanine aminotransferase, sits in high concentration inside liver cells, so more of it reaches the bloodstream when those cells are stressed.
In steatotic liver disease, fat inside the cells can sit alongside low grade inflammation, and that is the common explanation offered for a mildly raised ALT in someone carrying metabolic risk factors. The catch is sensitivity. Research suggests that liver enzyme levels are an unreliable way to detect steatosis on their own, because many people with fat in the liver have enzyme values inside the standard range 8.
Plenty of other things move this number. Hard training in the days before a draw, alcohol intake, viral hepatitis, gallbladder problems and certain medicines can all push ALT up. Recent illness can too.
So the sequence runs observation, then meaning, then next step. The observation is a value above your lab's upper limit. The possible meaning is liver cell strain from any of several sources. The next step is a repeat measurement and a review of your history with a clinician, who decides whether imaging or additional markers are warranted. Clinical practice guidelines published in 2026 set out how clinicians confirm steatosis and then assess the risk of fibrosis 9.
AST widens the picture because it comes from more than the liver, so its relationship to ALT is usually more informative than its own value. AST, aspartate aminotransferase, is present in liver cells but also in skeletal muscle, heart muscle and red blood cells.
That distribution is exactly why the two enzymes are read together. A long run, a heavy lifting block or a muscle strain can lift AST while the liver is doing nothing unusual. A clinician asks about recent training before drawing conclusions, and a repeat test after a quiet week often settles the question.
AST also feeds scoring tools built to answer a harder question, which is whether scarring has started. Research suggests that non-invasive scores combining AST with ALT, age and platelet count are useful for estimating the likelihood of advanced fibrosis 8. Those scores are a filter, not a verdict. They help a clinician decide who needs elastography or a specialist opinion.
Other things shift AST as well. Alcohol intake, red blood cell breakdown and some medicines all contribute. A single value sitting slightly outside the range is a prompt for context, not a conclusion about your liver.
GGT is checked because it helps separate a liver and bile duct pattern from other explanations, and because it reacts to alcohol. GGT, gamma-glutamyl transferase, sits on the membranes of the cells lining the small bile ducts, so it tends to rise when bile flow is obstructed or when the biliary system is irritated.
Its usefulness is also its limitation. GGT is sensitive and not specific, which means it moves in many situations and rarely identifies the cause by itself. Paired with a raised ALT it suggests the signal really is coming from the liver. Paired with a raised alkaline phosphatase it points toward the bile ducts.
Alcohol is the conversation GGT usually starts. Under-reporting here is common and unhelpful, because it sends the assessment down the wrong path.
Other influences include recent illness, body weight and some medicines. As with every marker on this page, a GGT result outside the standard range is suboptimal rather than conclusive, and it is worth discussing with a clinician who can see the whole panel.
They can, because the liver packages and exports triglycerides, so a high fasting value is part of the metabolic pattern that tends to accompany steatosis. Triglycerides are measured on a standard lipid panel, usually after an overnight fast.
Raised fasting triglycerides is one of the cardiometabolic criteria used when defining MASLD alongside evidence of fat in the liver, which is why the lipid panel is rarely skipped in this assessment 3. The marker is not a liver test in the enzyme sense. It describes the metabolic environment the liver is working in.
The stakes extend past the liver itself. Research suggests that cardiovascular disease is a leading cause of death in people with MASLD, so the lipid picture carries weight beyond what it says about hepatic fat 3.
Triglycerides are also one of the more variable markers on a panel. A meal close to the draw, alcohol the night before, an acute illness or poorly controlled blood sugar can all lift a single reading. That is why clinicians look at trend rather than one value, and why fasting instructions matter when the blood is drawn.
Because insulin resistance usually sits upstream of liver fat, and Fasting Insulin is one of the simplest ways to see it before fasting glucose or HbA1c drift out of range. Insulin is the hormone that moves glucose into cells, and when cells respond poorly the pancreas compensates by producing more of it.
Research suggests that insulin resistance is central to the accumulation of fat in liver cells 4. A high fasting insulin alongside a normal fasting glucose is a recognised pattern, and it is one possible reason a person with unremarkable routine bloodwork still carries metabolic risk.
The association runs in both directions in clinical practice. The American Diabetes Association consensus report recommends screening for steatotic liver disease in people with type 2 diabetes, which reflects how closely the two conditions track 5.
Fasting insulin is sensitive to context. Recent carbohydrate intake, a poor night of sleep, acute stress, illness and even the length of the fast all shift it. Assay methods differ between labs too, so comparing a result from one lab with a result from another is less reliable than repeating the test in the same place. A single elevated value is worth checking again rather than acting on alone.
Quite a lot, and this is where honesty matters more than reassurance. Normal enzymes do not rule out fat in the liver, since research suggests that enzyme levels are an unreliable screening signal for steatosis by themselves 8.
No routine blood test visualises the liver. Studies indicate that imaging, including ultrasound and stiffness measurement, carries the central role in identifying steatosis and estimating how fibrotic the tissue has become 1. Blood markers help decide who should have that imaging. They do not replace it.
Bloodwork also says nothing about the inputs that created the situation. It cannot see how many hours you sleep, how much you actually drink, how much muscle you carry, how consistently you train or how your weight has moved over two years. It cannot see untreated sleep apnoea or a stressful period at work. Those are history questions, and they often explain more than the numbers do.
Finally, a panel is a snapshot. It captures one morning, after one night of sleep, after one week of eating. A single draw showing everything inside range is useful information and no guarantee about the months around it. Repeating markers over time tells a far more honest story than any single result.
Seek prompt or urgent care if you notice yellowing of the skin or the whites of the eyes, dark urine with pale stools, severe or worsening pain in the upper right abdomen, swelling of the abdomen or legs, vomiting blood, black tarry stools, confusion, or unusual drowsiness. Fever alongside abdominal pain also warrants same day assessment.
These signs do not tell you what you have, and guessing at a diagnosis from a symptom list is unreliable. They tell you that someone with training needs to look at you soon rather than at your next routine appointment.
The same applies to results. A liver marker well outside the standard range is worth discussing with a clinician promptly, and no abnormal result should be ignored or explained away on your own. Bring the full report rather than one highlighted line, since the pattern across markers is what a clinician reads.
If you are having thoughts of self-harm, call or text 988 (US) or your local emergency number now.
A liver function panel measures the enzyme side of this picture, including ALT, AST and GGT, while triglycerides and fasting insulin sit on the metabolic side and are usually drawn at the same visit. Together they give a clinician enough to decide whether imaging or a fibrosis assessment is the sensible next move.
FitScript members have 150+ biomarkers tested per year, and Atlas, FitScript's AI health advisor, explains each result in plain language next to the standard reference range so the numbers are legible rather than intimidating. Interpretation is still a conversation, not an output.
Treatment decisions belong to a licensed provider who reviews your results, your history and your examination. This page is educational and is not medical advice. Discuss your results and any next step with a clinician or licensed provider before changing anything.
For a line by line walk through of how these enzymes are reported, read what do liver function tests show.
No single food drives or clears fat in the liver, so there is no one answer worth chasing. Nutrition changes are individual, and they work best when a clinician or registered dietitian sets the direction after seeing your bloodwork and your history. Start with testing, then have that conversation with a professional who knows your numbers.
Possibly, but the answer depends on the person rather than on a list. Fat in the liver sits downstream of overall energy balance, alcohol intake and metabolic health, so eating patterns matter more than individual foods. A clinician or dietitian who has your labs in front of them should set any specific guidance.
There is no best food for a fatty liver, and any source promising one is overselling it. What suits one person may not suit another, because alcohol intake, blood sugar control, medication history and body composition all shape the picture. Get your markers measured first, then work through the options with a qualified professional.
Yes. Normal ALT, AST and GGT do not rule out fat in the liver, which makes a clean panel reassuring rather than conclusive. Where metabolic risk factors are present, a clinician may still arrange imaging to look directly.
None of them show it directly. Blood tests show enzymes and metabolic markers that make liver fat more or less likely, while imaging such as ultrasound is what actually visualises the tissue. A clinician decides which combination makes sense for your situation.
Usually not. Some people describe a dull ache or fullness under the right ribs, because the capsule around the liver can stretch, while most feel nothing at all. Severe or worsening pain in that area needs urgent assessment rather than watchful waiting.
It can, which is why a clinician asks directly about intake. GGT in particular responds to alcohol, and the whole enzyme pattern is read differently depending on how much a person drinks. Be accurate about your intake, because guessing changes the interpretation.
Imaging is the usual next step, most often an ultrasound, sometimes with a stiffness measurement to assess scarring. Blood markers and the scores built from them help decide who needs that imaging and who needs a specialist opinion. A clinician makes that call from your full picture.